Update shared on05 Sep 2025
HUTCHMED (China)’s valuation outlook has improved with a notable drop in its future P/E ratio from 35.13x to 26.14x while net profit margin held steady, resulting in no change to the consensus analyst price target, which remains £3.62.
What's in the News
- Dr. Weiguo Su takes medical leave as CEO; CFO Johnny Cheng appointed Acting CEO while retaining CFO role.
- Full-year 2025 oncology revenue guidance revised to $270–350 million due to deferred milestone payments and delayed sovleplenib China NDA review.
- Patient enrollment completed for SANOVO Phase III trial (ORPATHYS + TAGRISSO) in first-line EGFRm, MET+ NSCLC; topline results expected in H2 2026 to support potential sNDA in China.
- Combination of ORPATHYS and TAGRISSO approved by China NMPA for post-EGFR TKI, MET-amplified advanced NSCLC, based on strong Phase II/III data (SAVANNAH, SACHI).
- SAFFRON global Phase III trial of ORPATHYS + TAGRISSO ongoing for registration filings in the US and globally; received US FDA Fast Track Designation.
Valuation Changes
Summary of Valuation Changes for HUTCHMED (China)
- The Consensus Analyst Price Target remained effectively unchanged, at £3.62.
- The Future P/E for HUTCHMED (China) has significantly fallen from 35.13x to 26.14x.
- The Net Profit Margin for HUTCHMED (China) remained effectively unchanged, at 15.56%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.